The oncology drug developer completed a Tianda and Accuron-backed series C round that initially closed at $34m last month, bringing its overall funding to $77m.
Singapore-based biotechnology company Aslan Pharmaceuticals closed a series C round featuring technology and engineering company Accuron and pharmaceutical company Tianda Pharmaceuticals at $43m on Thursday.
Accuron and Tianda joined Haitong International, Morningside Ventures, Bioveda Capital, Cenova Ventures and Sagamore Bioventures for the round’s $34m first close last month, before private equity firm MVP Capital Partners added the additional capital.
Aslan is developing oncology immunotherapies and targeted drugs that are focused on the types of tumours prevalent in Asia.
The…
